$0.64
0.16% day before yesterday
Nasdaq, Dec 27, 09:50 pm CET
ISIN
US09077B1044
Symbol
BCAB
Sector
Industry

BioAtla Inc Stock price

$0.64
-1.00 61.10% 1M
-0.83 56.60% 6M
-1.82 74.07% YTD
-2.54 79.94% 1Y
-18.64 96.69% 3Y
-17.36 96.46% 5Y
-17.36 96.46% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
-0.00 0.31%
ISIN
US09077B1044
Symbol
BCAB
Sector
Industry

Key metrics

Market capitalization $37.02m
Enterprise Value $-18.25m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.21
EV/Sales (TTM) EV/Sales -1.66
P/S ratio (TTM) P/S ratio 3.37
P/B ratio (TTM) P/B ratio 1.34
Revenue (TTM) Revenue $11.00m
EBIT (operating result TTM) EBIT $-86.24m
Free Cash Flow (TTM) Free Cash Flow $-85.08m
Cash position $56.52m
EPS (TTM) EPS $-1.70
P/E forward negative
P/S forward 3.37
EV/Sales forward negative
Short interest 9.21%
Show more

Is BioAtla Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

BioAtla Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a BioAtla Inc forecast:

3x Buy
75%
1x Hold
25%

Analyst Opinions

4 Analysts have issued a BioAtla Inc forecast:

Buy
75%
Hold
25%

Financial data from BioAtla Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
11 11
-
100%
- Direct Costs 1.07 1.07
7% 7%
10%
9.94 9.94
964% 964%
90%
- Selling and Administrative Expenses 21 21
14% 14%
191%
- Research and Development Expense 74 74
28% 28%
674%
-85 -85
34% 34%
-774%
- Depreciation and Amortization 1.07 1.07
7% 7%
10%
EBIT (Operating Income) EBIT -86 -86
34% 34%
-784%
Net Profit -82 -82
34% 34%
-744%

In millions USD.

Don't miss a Thing! We will send you all news about BioAtla Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

BioAtla Inc Stock News

Neutral
GlobeNewsWire
9 days ago
SAN DIEGO, Dec. 20, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company (“BioAtla” or the “Company”) focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it has entered into definitive agreements with certain institutional investors for the issuance and sal...
Neutral
GlobeNewsWire
13 days ago
Improved median overall survival (OS) for Mec-V treated patients with treatment-refractory non-small cell lung cancer (NSCLC) expressing mutated KRAS (mKRAS) as compared to Mec-V treated patient with treatment-refractory NSCLC expressing wild-type KRAS (wtKRAS)
Neutral
GlobeNewsWire
19 days ago
SAN DIEGO, Dec. 10, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced a poster presentation at the upcoming International Association for the Study of Lung Cancer (IASLC) 2024 Hot Topic in Basic & Translatio...
More BioAtla Inc News

Company Profile

BioAtla, Inc. engages in the development of novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its CAB portfolio include MABs & ADCS, BA3011, and BA3021. The company was founded by Jay M. Short and Carolyn Anderson in March 2007 and is headquartered in San Diego, CA.

Head office United States
CEO Jay Short
Employees 65
Founded 2007
Website www.BioAtla.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today